Ken Kato

机构：National Cancer Centre Japan, National Cancer Center, Osaka National Hospital, National Cancer Center Hospital East · ORCID：0000-0002-1733-5072

发表论文 844 篇 · 总被引 31636 次 · h-index 77

代表论文

• Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial (2025 · Nature Medicine · 被引 19)
• Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 15)
• Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up (2025 · Advances in Therapy · 被引 3)
• Association Between Immune‐Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study (2025 · Cancer Medicine · 被引 3)
• The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma (2025 · Esophagus · 被引 1)
• Safety and short-term efficacy of neoadjuvant FLOT therapy in cisplatin-unfit patients with resectable esophageal squamous cell carcinoma (2025 · Esophagus · 被引 1)